Systemic Lupus Erythematosus - Pipeline Review, Q1 2011
Global Markets Direct, February 2011, Pages: 75
Systemic Lupus Erythematosus - Pipeline Review, Q1 2011
Summary
Global Markets Direct’s, 'Systemic Lupus Erythematosus - Pipeline Review, Q1 2011', provides an overview of the Systemic Lupus Erythematosus therapeutic pipeline. This report provides information on the therapeutic development for Systemic Lupus Erythematosus, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Systemic Lupus Erythematosus. 'Systemic Lupus Erythematosus - Pipeline Review, Q1 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Systemic Lupus Erythematosus.
- A review of the Systemic Lupus Erythematosus products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Systemic Lupus Erythematosus pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Systemic Lupus Erythematosus.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Systemic Lupus Erythematosus pipeline depth and focus of Systemic Lupus Erythematosus therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Systemic Lupus Erythematosus Overview
Therapeutics Development
An Overview of Pipeline Products for Systemic Lupus Erythematosus
Systemic Lupus Erythematosus Therapeutics under Development by Companies
Systemic Lupus Erythematosus Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Companies Involved in Systemic Lupus Erythematosus Therapeutics Development
Bristol-Myers Squibb Company
Boehringer Ingelheim GmbH
F. Hoffmann-La Roche Ltd.
Amgen Inc.
AstraZeneca PLC
Eli Lilly and Company
GlaxoSmithKline plc
Biotest AG
Novo Nordisk A/S
Plexxikon Inc.
Cephalon, Inc.
Human Genome Sciences, Inc.
Pfizer Inc.
UCB Group
Celgene Corporation
Onyx Pharmaceuticals, Inc.
Merck KGaA
Genesis Research and Development Corporation Ltd.
Hollis-Eden Pharmaceuticals, Inc.
Active Biotech AB
Idera Pharmaceuticals, Inc.
Compugen Ltd.
Dynavax Technologies Corporation
Protalex, Inc.
Neovacs SA
CREABILIS Therapeutics S.r.l.
MAT Biopharma
Argos Therapeutics, Inc.
Astion Pharma A/S
Theraclone Sciences, Inc.
Cornerstone Therapeutics Inc.
ChemoCentryx, Inc.
Taligen Therapeutics Inc.
Anthera Pharmaceuticals‚ Inc.
SuppreMol GmbH
Advanced Cancer Therapeutics
Zenyaku Kogyo Co., Ltd.
Ampio Pharmaceuticals, Inc.
Universities/Institutes Involved in Systemic Lupus Erythematosus Therapeutics Development
Systemic Lupus Erythematosus - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Late Stage Drug Profiles – Companies
Anti BAFF Human Antibody - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Atacicept - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Benlysta - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Epratuzumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Orencia - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Prestara - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Rituxan + Prednisone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Rituximab + Methylprednisolone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Late Stage Drug Profiles – Universities/Institutes
Atorvastatin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
azathioprine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
cyclophosphamide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cyclophosphamide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Infliximab + Azathioprine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Prevenar + Pneumo23 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Discontinued Products
Systemic Lupus Erythematosus - Featured News
1. Dec 14, 2010: Anthera Selects Merck BioManufacturing Network As Manufacturing Supplier For A-623
2. Dec 14, 2010: Immunomedics And UCB Initiate Phase III Program With Epratuzumab In Systemic Lupus Erythematosus
3. Dec 07, 2010: Argos Initiates Phase I Clinical Trial Of AGS-009 For Treatment Of Systemic Lupus Erythematosus
4. Dec 03, 2010: GSK And Human Genome Sciences Announce FDA Extension Of Benlysta PDUFA Target Date
5. Nov 16, 2010: Anthera Suspends Enrollment And Dosing In PEARL-SC Clinical Trial To Address Reports Of Vial Problems
6. Nov 16, 2010: Human Genome Sciences And GSK Announce Vote Of FDA Advisory Committee To Recommend Approval Of Benlysta For Systemic Lupus Erythematosus
7. Nov 15, 2010: Neovacs Receives DSMB Authorization To Proceed To Fourth Dose Level Of Ifna-Kinoid In Phase I/II Trial In Lupus
8. Oct 06, 2010: Myrexis To Present Oral Anti-Interferon Program At American College of Rheumatology/Association Of Rheumatology Health Professionals
9. Sep 27, 2010: Neovacs Receives DSMB Approval For IFNa-Kinoid In Phase I/II Study In Lupus Patients
10. Aug 19, 2010: HGS And GSK Receive FDA Priority Review Designation For Benlysta For Treatment Of Systemic Lupus Erythematosus
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products Under Development for Systemic Lupus Erythematosus, 2011
Products under Development for Systemic Lupus Erythematosus – Comparative Analysis, 2011
Comparative Analysis by Late Stage Development, 2011
Comparative Analysis by Mid Clinical Stage Development, 2011
Comparative Analysis by Early Clinical Stage Development, 2011
Comparative Analysis by Discovery and Pre-Clinical Stage Development, 2011
Bristol-Myers Squibb Company, 2011
Boehringer Ingelheim GmbH, 2011
F. Hoffmann-La Roche Ltd., 2011
Amgen Inc., 2011
AstraZeneca PLC, 2011
Eli Lilly and Company, 2011
GlaxoSmithKline plc, 2011
Biotest AG, 2011
Novo Nordisk A/S, 2011
Plexxikon Inc., 2011
Cephalon, Inc., 2011
Human Genome Sciences, Inc., 2011
Pfizer Inc., 2011
UCB Group, 2011
Celgene Corporation, 2011
Onyx Pharmaceuticals, Inc., 2011
Merck KGaA, 2011
Genesis Research and Development Corporation Ltd., 2011
Hollis-Eden Pharmaceuticals, Inc., 2011
Active Biotech AB, 2011
Idera Pharmaceuticals, Inc., 2011
Compugen Ltd., 2011
Dynavax Technologies Corporation, 2011
Protalex, Inc., 2011
Neovacs SA, 2011
CREABILIS Therapeutics S.r.l., 2011
MAT Biopharma, 2011
Argos Therapeutics, Inc., 2011
Astion Pharma A/S, 2011
Theraclone Sciences, Inc., 2011
Cornerstone Therapeutics Inc., 2011
ChemoCentryx, Inc., 2011
Taligen Therapeutics Inc., 2011
Anthera Pharmaceuticals‚ Inc., 2011
SuppreMol GmbH, 2011
Advanced Cancer Therapeutics, 2011
Zenyaku Kogyo Co., Ltd., 2011
Ampio Pharmaceuticals, Inc., 2011
Assessment by Monotherapy Products, 2011
Assessment by Combination Products
Assessment by Stage and Route of Administration, 2011
Assessment by Molecule Type, 2011
Discontinued Products
List of Figures
Number of Products under Development for Systemic Lupus Erythematosus, 2011
Products under Development for Systemic Lupus Erythematosus – Comparative Analysis, 2011
Products under Development by Companies, 2011
Products under Investigation by Universities/Institutes, 2011
Late Stage Products, 2011
Mid Clinical Stage Products, 2011
Early Clinical Stage Products, 2011
Discovery and Pre-Clinical Stage Products, 2011
Assessment by Monotherapy Products, 2011
Assessment by Combination Products, 2011
Assessment by Route of Administration, 2011
Assessment by Stage and Route of Administration, 2011
Assessment by Molecule Type, 2011
Assessment by Stage and Molecule Type, 2011
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW5
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
